CWP
LGND icon

Concord Wealth Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Concord Wealth Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12
Closed -$1.29K – 894
2024
Q4 		$1.29K Hold
12
– – ﹤0.01% 761
2024
Q3 		$1.2K Buy
+12
New +$1.21K ﹤0.01% 803
2022
Q3 		– Sell
-6
Closed – – 695
2022
Q2 		$0 Sell
6
-247
-98% -$14K ﹤0.01% 1314
2022
Q1 		$18K Hold
253
– – ﹤0.01% 653
2021
Q4 		$24K Buy
253
+93
+58% +$8.59K 0.01% 603
2021
Q3 		$14K Buy
160
+57
+55% +$4.41K 0.01% 426
2021
Q2 		$8K Buy
+103
New +$8.57K ﹤0.01% 665

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concord Wealth Partners's LGND Position: Q1 2025 in Review

Concord Wealth Partners sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 12 shares — an estimated $1.29K sold.

Concord Wealth Partners first reported a position in LGND in Q2 2021 and held it in 7 quarters. The position peaked at $24K in Q4 2021. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

  • Concord Wealth Partners reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Concord Wealth Partners sold 12 Ligand Pharmaceuticals shares in Q1 2025, an estimated $1.29K.
  • Concord Wealth Partners first reported a position in Ligand Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Concord Wealth Partners's Ligand Pharmaceuticals position peaked at $24K in Q4 2021.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on Concord Wealth Partners's 13F filing for Q1 2025, filed 2 May 2025.